Karter Andrew J, Lipska Kasia J, O'Connor Patrick J, Liu Jennifer Y, Moffet Howard H, Schroeder Emily B, Lawrence Jean M, Nichols Gregory A, Newton Katherine M, Pathak Ram D, Desai Jay, Waitzfelder Beth, Butler Melissa G, Thomas Abraham, Steiner John F
Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612.
Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, PO Box 208020, New Haven, CT 06520.
J Diabetes Complications. 2017 May;31(5):869-873. doi: 10.1016/j.jdiacomp.2017.02.009. Epub 2017 Feb 21.
Seven-year surveillance study (2005-2011) to evaluate race/ethnic differences in the trends in rates of severe hypoglycemia (SH) in a population of insured, at-risk adults with diabetes.
SH events were identified via any primary or principal diagnosis from emergency department or inpatient encounters among African American, Asian, Latino and White adult diabetes patients treated with insulin or secretagogues (Sulfonylureas or Meglitinides), receiving care from integrated healthcare delivery systems across the United States. We calculated age- and sex-standardized annual SH rates and average annual percent change (AAPC) in SH rates.
Annual SH rates ranged from 1.8% to 2.1% during this 7-year observation period (2,200,471 person-years). African Americans had consistently higher SH rates compared with Whites, while Latinos and Asians had consistently lower rates compared with Whites in each of the 7 years (all p < 0.01). The trend increased significantly only among African Americans (AAPC = +4.3%; 95% CI: +2.1, +6.5%); in the other groups, the AAPC was not significantly different from zero.
Surveillance efforts should monitor the racial/ethnic-specific rates. The factors underlying substantially higher rates of hypoglycemia in African Americans should be evaluated. Clinically and culturally-appropriate strategies to reduce the risk of SH need to be developed and tested.
开展为期七年的监测研究(2005 - 2011年),以评估患有糖尿病的参保高危成年人群中严重低血糖(SH)发生率趋势的种族/族裔差异。
通过美国综合医疗服务体系中接受胰岛素或促分泌剂(磺脲类或格列奈类)治疗的非裔美国、亚洲、拉丁裔和白人成年糖尿病患者在急诊科或住院治疗时的任何主要或首要诊断来确定SH事件。我们计算了年龄和性别标准化的年度SH发生率以及SH发生率的年均变化百分比(AAPC)。
在这7年的观察期内(2200471人年),年度SH发生率在1.8%至2.1%之间。在这7年中的每一年,非裔美国人的SH发生率始终高于白人,而拉丁裔和亚洲人的发生率始终低于白人(所有p < 0.01)。仅在非裔美国人中趋势显著增加(AAPC = +4.3%;95% CI:+2.1,+6.5%);在其他组中,AAPC与零无显著差异。
监测工作应监测特定种族/族裔的发生率。应评估非裔美国人低血糖发生率显著较高的潜在因素。需要制定并测试临床和文化适宜的策略以降低SH风险。